Literature DB >> 24145605

Truncation of gene F5L partially masks rescue of vaccinia virus strain MVA growth on mammalian cells by restricting plaque size.

Bianca M Dobson1, David C Tscharke1.   

Abstract

Modified vaccinia virus Ankara (MVA) is a candidate vaccine vector that is severely attenuated due to mutations acquired during several hundred rounds of serial passage in vitro. A previous study used marker rescue to produce a set of MVA recombinants with improved replication on mammalian cells. Here, we extended the characterization of these rescued MVA strains and identified vaccinia virus (VACV) gene F5L as a determinant of plaque morphology but not replication in vitro. F5 joins a growing group of VACV proteins that influence plaque formation more strongly than virus replication and which are disrupted in MVA. These defective genes in MVA confound the interpretation of marker rescue experiments designed to map mutations responsible for the attenuation of this important VACV strain.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24145605     DOI: 10.1099/vir.0.058495-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  2 in total

1.  SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells.

Authors:  Ruikang Liu; Jorge D Mendez-Rios; Chen Peng; Wei Xiao; Andrea S Weisberg; Linda S Wyatt; Bernard Moss
Journal:  PLoS Pathog       Date:  2019-05-30       Impact factor: 6.823

2.  Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses.

Authors:  María Pía Holgado; Juliana Falivene; Cynthia Maeto; Micaela Amigo; María Fernanda Pascutti; María Belén Vecchione; Andrea Bruttomesso; Gabriela Calamante; María Paula Del Médico-Zajac; María Magdalena Gherardi
Journal:  Viruses       Date:  2016-05-23       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.